A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With ALS

Full Study Summary:

• Eligibility Criteria

  Gender:

  Female, Male

  Minimum Age:

  18

  Maximum Age:

  N/A

  Min Vital Capacity (% predicted normal):

  65

  Time since Symptom Onset:

  Time since Diagnosis:

  Can participants use Riluzole?

  Yes

  
  

  Key Inclusion Criteria:

  Must meet the laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria.
  Participants taking concomitant riluzole at study entry must be on a stable dose for greater than or equals to (>=) 30 days prior to the first dose of study treatment (Day 1). Participants taking concomitant riluzole must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that riluzole should be discontinued for medical reasons, in which case it may not be restarted during the study.
  Participants taking concomitant edaravone at study entry must be on a stable dose for >= 60 days prior to the first dose of study treatment (Day 1).
  Adequate respiratory function as indicated by slow vital capacity (SVC) >= 65% of predicted value as adjusted for sex, age, and height (from the sitting position).

  Key Exclusion Criteria:

  Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that would, in the opinion of the Investigator, interfere with the conduct or assessments of the study.
  Significant cognitive impairment or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression less than or equals to (<=) 90 days of Screening, which in the opinion of the Investigator would interfere with the study procedures.
  Treatment with drugs that are transported by Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) including, but not limited to, rosuvastatin, sulfasalazine, dabigatran, digoxin and fexofenadine.
  Current enrollment or plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 30 days or 5 half-lives of the agent, whichever is longer, prior to the Baseline Visit (pre-dose on Day 1). Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator and after consultation with the Sponsor.

• Site Contact Information

  Barrow Neurological Institute
  .(JavaScript must be enabled to view this email address) / Phoenix, Arizona 85013
  United States

  University of California San Diego
  Rosemarie Previte / .(JavaScript must be enabled to view this email address) / 858-246-1319
  San Diego, California 92121
  United States

  Mayo Clinic Hospital
  .(JavaScript must be enabled to view this email address) / 904-953-6912
  Jacksonville, Florida 32224
  United States

  University of South Florida
  Tampa, Florida 33620
  United States

  Johns Hopkins Hospital
  .(JavaScript must be enabled to view this email address) / 410-502-0495
  Baltimore, Maryland 21224
  United States

  Massachusetts General Hospital
  Isabel Anez / .(JavaScript must be enabled to view this email address) / 617-643-2499
  Yuriko Fukumara / .(JavaScript must be enabled to view this email address) / 617-643-2522
  Boston, Massachusetts 02114
  United States

  Washington University
  Saint Louis, Missouri 63110
  United States

  Research Site
  Lincoln, Nebraska 68506
  United States

  Alliance for Multispecialty Research NOCCR/VRG
  865-305-9100 ext 302 or 303
  Knoxville, Tennessee 37920
  United States